BLAB Stock Overview
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally.
Britannia Life Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.14|
|52 Week High||CA$0.32|
|52 Week Low||CA$0.085|
|1 Month Change||38.10%|
|3 Month Change||7.41%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-46.30%|
Recent News & Updates
|BLAB||CA Professional Services||CA Market|
Return vs Industry: Insufficient data to determine how BLAB performed against the Canadian Professional Services industry.
Return vs Market: Insufficient data to determine how BLAB performed against the Canadian Market.
|BLAB Average Weekly Movement||17.4%|
|Professional Services Industry Average Movement||8.7%|
|Market Average Movement||10.6%|
|10% most volatile stocks in CA Market||18.9%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: BLAB is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: BLAB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.
Britannia Life Sciences Fundamentals Summary
|BLAB fundamental statistics|
Is BLAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLAB income statement (TTM)|
|Cost of Revenue||CA$2.03m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.095|
|Net Profit Margin||-211.76%|
How did BLAB perform over the long term?See historical performance and comparison
Is BLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLAB?
Other financial metrics that can be useful for relative valuation.
|What is BLAB's n/a Ratio?|
Price to Sales Ratio vs Peers
How does BLAB's PS Ratio compare to its peers?
|BLAB PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
GSL Green Scientific Labs Holdings
BLAB Britannia Life Sciences
Price-To-Sales vs Peers: BLAB is good value based on its Price-To-Sales Ratio (3.2x) compared to the peer average (4.1x).
Price to Earnings Ratio vs Industry
How does BLAB's PE Ratio compare vs other companies in the North American Professional Services Industry?
Price-To-Sales vs Industry: BLAB is expensive based on its Price-To-Sales Ratio (3.2x) compared to the Canadian Professional Services industry average (2.2x)
Price to Sales Ratio vs Fair Ratio
What is BLAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.2x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BLAB's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of BLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BLAB (CA$0.15) is trading below our estimate of fair value (CA$3.93)
Significantly Below Fair Value: BLAB is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Britannia Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Commercial Services industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Britannia Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Britannia Life Sciences is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Britannia Life Sciences competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Britannia Life Sciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BLAB is currently unprofitable.
Growing Profit Margin: BLAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BLAB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLAB is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (21.1%).
Return on Equity
High ROE: BLAB has a negative Return on Equity (-255.08%), as it is currently unprofitable.
Discover strong past performing companies
How is Britannia Life Sciences's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BLAB's short term assets (CA$3.5M) do not cover its short term liabilities (CA$8.3M).
Long Term Liabilities: BLAB's short term assets (CA$3.5M) do not cover its long term liabilities (CA$7.3M).
Debt to Equity History and Analysis
Debt Level: BLAB's net debt to equity ratio (61.7%) is considered high.
Reducing Debt: Insufficient data to determine if BLAB's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BLAB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BLAB is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 143.8% per year.
Discover healthy companies
What is Britannia Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLAB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BLAB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pete Shippen (41 yo)
Mr. Peter James Shippen, also known as Pete, CPA, CAIA, serves as Director of Myplas USA, Inc. He served as the President at Redwood Asset Management Inc. since September 2009 and served as the firm’s Chie...
Experienced Management: BLAB's management team is considered experienced (3.6 years average tenure).
Experienced Board: BLAB's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: BLAB only recently listed within the past 12 months.
Britannia Life Sciences Inc.'s employee growth, exchange listings and data sources
- Name: Britannia Life Sciences Inc.
- Ticker: BLAB
- Exchange: CNSX
- Founded: NaN
- Industry: Research and Consulting Services
- Sector: Commercial Services
- Implied Market Cap: CA$23.524m
- Shares outstanding: 162.23m
- Website: https://britannia.life
Number of Employees
- Britannia Life Sciences Inc.
- 120 Adelaide Street West
- Suite 2400
- M5H 1T1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.